Lexology July 21, 2025
In June 2025, China’s Center for Drug Evaluation (“CDE”), which is one of the specialized product centers affiliated with China’s chief drug regulator, the National Medical Products Administration (“NMPA”), released a report titled “Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2024).” The report presents data on clinical trials in China in the past year, including the number of trials for different types of products (small molecule drugs, biologics, and traditional Chinese medicinal products), different disease areas, and different phases of trials. The report also analyzes the geographical distribution, implementation status, and quality control of clinical trials in China. According to CDE, the release of the report is to “showcase the current status of...
Today's Sponsors
Today's Sponsor